Table 1. Characteristics of Patients With PSP and Controls.
| Characteristic | Patients With PSP (N = 802) | Controls (N = 1312) |
|---|---|---|
| Age, median (range), ya | 75 (52-98) | 69 (45-92) |
| Sex, No. (%) | ||
| Female | 376 (46.9) | 701 (53.4) |
| Male | 426 (53.1) | 611 (46.6) |
| Braak stage, No. (%) | ||
| 0 | 117 (14.6) | NA |
| I | 133 (16.6) | NA |
| II | 235 (29.3) | NA |
| III | 247 (30.8) | NA |
| IV | 52 (6.5) | NA |
| V | 12 (1.5) | NA |
| VI | 6 (0.8) | NA |
| Thal phase, No. (%) | ||
| 0 | 356 (44.4) | NA |
| 1 | 133 (16.6) | NA |
| 2 | 54 (6.7) | NA |
| 3 | 195 (24.3) | NA |
| 4 | 43 (5.4) | NA |
| 5 | 21 (2.6) | NA |
| CB overall tau pathology score, median (range)b | 1.5 (0.3-2.4) | NA |
| NFT overall tau pathology score, median (range)b | 2.2 (0.8-2.9) | NA |
| TA overall tau pathology score, median (range)b | 1.0 (0.1-2.1) | NA |
| NT overall tau pathology score, median (range)b | 2.2 (0.3-2.9) | NA |
Abbreviations: CB, coiled bodies; NA, not applicable; NFT, neurofibrillary tangles; NT, neuropil threads; PSP, progressive supranuclear palsy; TA, tufted astrocytes.
Age at death is given for patients with PSP; age at blood collection is given for controls.
One overall score was created for each separate measure of tau pathology (NFT, CB, TA, and NT) by calculating the mean of the semiquantitative measures (0, 1, 2, or 3) for each patient with PSP across all neuroanatomical regions. For patients who did not have information available regarding the given measure of tau pathology for a given neuroanatomical region, these scores were imputed by using the mean of the values of the patients with PSP who did have this information available for the purposes of calculating the overall scores. Any patient with missing data for greater than 50% of the neuroanatomical regions for a given measure of tau pathology was not included in any analysis involving the overall score for that measure. Overall tau pathology scores were unavailable for CB (1 patient), TA (31 patients), and NT (1 patient).